BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24862665)

  • 21. Neuroendocrine Tumors of the Stomach.
    Corey B; Chen H
    Surg Clin North Am; 2017 Apr; 97(2):333-343. PubMed ID: 28325190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
    Luboldt W; Hartmann H; Wiedemann B; Zöphel K; Luboldt HJ
    Mol Imaging; 2010 Dec; 9(6):351-8. PubMed ID: 21084031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Neuroendocrine tumors of the stomach. Surgery therapy and prognosis].
    Bektas H; Länger F; Piso P; Werner U; Musholt TJ; Lehner F; Becker T; Klempnauer J
    Chirurg; 2002 Apr; 73(4):331-5. PubMed ID: 12063917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastric neuroendocrine neoplasms: a primer for radiologists.
    Roseland ME; Francis IR; Shampain KL; Stein EB; Wasnik AP; Millet JD
    Abdom Radiol (NY); 2022 Dec; 47(12):3993-4004. PubMed ID: 35411433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors.
    Sandström M; Velikyan I; Garske-Román U; Sörensen J; Eriksson B; Granberg D; Lundqvist H; Sundin A; Lubberink M
    J Nucl Med; 2013 Oct; 54(10):1755-9. PubMed ID: 23929824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
    Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
    Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.
    Lococo F; Cesario A; Paci M; Filice A; Versari A; Rapicetta C; Ricchetti T; Sgarbi G; Alifano M; Cavazza A; Treglia G
    Tumour Biol; 2014 Sep; 35(9):8369-77. PubMed ID: 24850179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
    Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
    Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum.
    Ilhan H; Fendler WP; Cyran CC; Spitzweg C; Auernhammer CJ; Gildehaus FJ; Bartenstein P; Angele MK; Haug AR
    Ann Surg Oncol; 2015 Jan; 22(1):164-71. PubMed ID: 25190113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Detection of a neuroendocrine differentiated cystic pancreatic lesion by gallium-68-DOTATOC-PET/CT with inconclusive MRI, CT and ultrasound diagnosis].
    Fröling V; Denecke T; Pöllinger A; Schreiter NF
    Rofo; 2010 Feb; 182(2):175-7. PubMed ID: 19998214
    [No Abstract]   [Full Text] [Related]  

  • 32. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?
    McCarthy DM
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.
    Malmberg C; Ripa RS; Johnbeck CB; Knigge U; Langer SW; Mortensen J; Oturai P; Loft A; Hag AM; Kjær A
    J Nucl Med; 2015 Dec; 56(12):1895-900. PubMed ID: 26429961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
    Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
    Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of positive
    Zilli A; Fanetti I; Conte D; Massironi S
    Clin Imaging; 2018; 49():156-158. PubMed ID: 29529451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
    Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
    Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    Hope TA; Pampaloni MH; Nakakura E; VanBrocklin H; Slater J; Jivan S; Aparici CM; Yee J; Bergsland E
    Abdom Imaging; 2015 Aug; 40(6):1432-40. PubMed ID: 25820755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.